MicroRNAs in prostate cancer: From biomarkers to molecularly-based therapeutics

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 4, 2012, Pages 314-319

  Gordanpour, A ^a   Nam, R K ^b   Sugar, L ^b   Seth, A ^a,b  

^a Sunnybrook Health Sciences Centre   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

biomarker; microRNA; therapeutics

Indexed keywords

MGN 4893; MICRORNA; MICRORNA 15A; MICRORNA 16 1; MICRORNA 17 3P; MICRORNA 203; MICRORNA 205; MICRORNA 21; MICRORNA 331; MICRORNA 34A; MICRORNA 3P; MIRAVIRSEN; ORPHAN DRUG; SMALL INTERFERING RNA; SURVIVIN; TRANSCRIPTION FACTOR RUNX2; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; DOWN REGULATION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; GENE EXPRESSION; HEPATITIS C; HUMAN; METASTASIS; MICROARRAY ANALYSIS; NONHUMAN; ONCOGENE; PATHOGENESIS; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REVIEW; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; UPREGULATION;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MOLECULAR TARGETED THERAPY; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84869220331     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2012.3     Document Type: Review

References (67)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
2. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 50 UTR as in the 30 UTR. Proc Natl Acad Sci USA 2007; 104: 9667-9672. (Pubitemid 47175324)
3. Duursma AM, Kedde M, Schrier M, le SC, Agami R. miR-148 targets human DNMT3b protein coding region. RNA 2008; 14: 872-877. (Pubitemid 351574909)
4. Khraiwesh B, Arif MA, Seumel GI, Ossowski S, Weigel D, Reski R et al. Transcriptional control of gene expression by microRNAs. Cell 2010; 140: 111-122.
5. Gonzalez S, Pisano DG, Serrano M. Mechanistic principles of chromatin remodeling guided by siRNAs and miRNAs. Cell Cycle 2008; 7: 2601-2608.
6. Kim DH, Saetrom P, Snove Jr O, Rossi JJ. MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci USA 2008; 105: 16230-16235.
7. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 50UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008; 30: 460-471. (Pubitemid 351672378)
8. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529. (Pubitemid 35403967)
9. Kozomara A, Griffiths-Jones S. MiRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39 (Database issue): D152-D157.
10. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
11. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res 2008; 36 (Database issue): D149-D153. (Pubitemid 351149712)
12. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500. (Pubitemid 40617277)
13. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115: 787-798. (Pubitemid 38058492)
14. Reinhart BJ, Weinstein EG, Rhoades MW, Bartel B, Bartel DP. MicroRNAs in plants. Genes Dev 2002; 16: 1616-1626. (Pubitemid 34743323)
15. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83-86. (Pubitemid 38055775)
16. Xu P, Vernooy SY, Guo M, Hay BA. The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr Biol 2003; 13: 790-795. (Pubitemid 36531030)
17. Bueno MJ, Pé rez de Castro I, Malumbres M. Control of cell proliferation pathways by microRNAs. Cell Cycle 2008; 7: 3143-3148.
18. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Møller S, Trapman J et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2011 (e-pub ahead of print 18 July 2011).
19. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008; 68: 6162-6170.
20. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130-6135. (Pubitemid 47037493)
21. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010; 126: 1166-1176.
22. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009; 16: 206-216.
23. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261. (Pubitemid 43271657)
24. Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Sacca M, Memeo L et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 2011; 30: 4231-4242.
25. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518.
26. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007; 13: 1668-1674. (Pubitemid 47481675)
27. Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem 2009; 284: 24696-24704.
28. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322: 1695-1699.
29. Yang K, Handorean AM, Iczkowski KA. MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro. Int J Clin Exp Pathol 2009; 2: 361-369.
30. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009; 28: 1714-1724.
31. Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M et al. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 2008; 3: e4029.
32. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14: 1271-1277.
33. Mihelich BL, Khramtsova EA, Arva N, Vaishnav A, Johnson DN, Giangreco AA et al. The miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. J Biol Chem 2011; 286: 44503-44511.
34. Viticchie G, Lena AM, Latina A, Formosa A, Gregersen LH, Lund AH et al. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle 2011; 10: 1121-1131.
35. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009; 69: 2287-2295.
36. Lee KH, Chen YL, Yeh SD, Hsiao M, Lin JT, Goan YG et al. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 2009; 28: 3360-3370.
37. Hurst DR, Edmonds MD, Welch DR. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 2009; 69: 7495-7498.
38. Watahiki A, Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M et al. MicroRNAs associated with metastatic prostate cancer. PLoS One 2011; 6: e24950.
39. Leite KR, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, Sanudo A et al. Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol 2011; 29: 265-269.
40. Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z et al. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem 2011; 350: 207-213.
41. Peng X, Guo W, Liu T, Wang X, Tu X, Xiong D et al. Identification of miRs-143 and-145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 2011; 6: e20341.
42. Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N et al. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 2011; 106: 405-413.
43. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormonerefractory prostate cancer. RNA 2008; 14: 417-424. (Pubitemid 351397806)
44. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Camara-Lopes LH et al. MicroRNA expression profiles in the progression of prostate cancer-from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol 2011 (e-pub ahead of print 29 August 2011).
45. Huang Q, Gumireddy K, Schrier M, le SC, Nagel R, Nair S et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008; 10: 202-210. (Pubitemid 351194050)
46. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010; 18: 181-187.
47. Zhang X, Ladd A, Dragoescu E, Budd WT, Ware JL, Zehner ZE. MicroRNA-17-3p is a prostate tumor suppressor in vitro and in vivo, and is decreased in high grade prostate tumors analyzed by laser capture microdissection. Clin Exp Metastasis 2009; 26: 965-979.
48. Schramedei K, Morbt N, Pfeifer G, Lauter J, Rosolowski M, Tomm JM et al. MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene 2011; 30: 2975-2985.
49. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR et al. miR-200 regulates PDGFD-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009; 27: 1712-1721.
50. Steele R, Mott JL, Ray RB. MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells. Genes Cancer 2010; 1: 381-387.
51. Saini S, Majid S, Yamamura S, Tabatabai ZL, Suh SO, Shahryari V et al. Regulatory role of miR-203 in prostate cancer progression and metastasis. Clin Cancer Res 2011; 17: 5287-5298.
52. Majid S, Dar AA, Saini S, Yamamura S, Hirata H, Tanaka Y et al. MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 2010; 116: 5637-5649.
53. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008; 377: 114-119.
54. Gordanpour A, Stanimirovic A, Nam RK, Moreno CS, Sherman C, Sugar L et al. miR-221 Is Down-regulated in TMPRSS2:ERG Fusion-positive Prostate Cancer. Anticancer Res 2011; 31: 403-410.
55. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010; 127: 394-403.
56. Musiyenko A, Bitko V, Barik S. Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J Mol Med 2008; 86: 313-322.
57. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17: 211-215.
58. Huang Y, Zou Q, Song H, Song F, Wang L, Zhang G et al. A study of miRNAs targets prediction and experimental validation. Protein Cell 2010; 1: 979-986.
59. Seto AG. The road toward microRNA therapeutics. Int J Biochem Cell Biol 2010; 42: 1298-1305.
60. Kasinski AL, Slack FJ. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11: 849-864.
61. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
62. Petrocca F, Lieberman J. Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol 2011; 29: 747-754.
63. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010; 70: 5923-5930.
64. McLaughlin J, Cheng D, Singer O, Lukacs RU, Radu CG, Verma IM et al. Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics. Proc Natl Acad Sci USA 2007; 104: 20501-20506.
65. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010; 70: 7027-7030.
66. Zuhorn IS, Engberts JB, Hoekstra D. Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J 2007; 36: 349-362. (Pubitemid 46626209)
67. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541. (Pubitemid 44050158)